Shuttle Pharmaceuticals Holdings Inc SHPH

NAS: SHPH | ISIN: US8256932034   17/05/2024
0,401 USD (-2,84%)
(-2,84%)   17/05/2024

22 maart 2024 · Shuttle Pharma Provides Fourth Quarter 2023 Corporate Update · Persbericht

13 februari 2024 · Shuttle Pharma Announces Its Intent to Pursue a Rights Offering · Persbericht

23 januari 2024 · Shuttle Pharma to Participate in a Fireside Chat at the Lytham Partners 2024 Investor Select Conference on February 1, 2024 · Persbericht

8 januari 2024 · Shuttle Pharmaceuticals Receives FDA Approval to Proceed with Phase II Clinical Trial of Ropidoxuridine for Treatment of Patients with Glioblastoma · Persbericht

11 december 2023 · Shuttle Pharmaceuticals Submits IND Application to the U.S. FDA for Ropidoxuridine Phase II Clinical Trial for Patients with Glioblastoma · Persbericht

31 oktober 2023 · Shuttle Pharma Advances Prostate Cancer Predictive Biomarker Program Through Exclusive License Agreement · Persbericht

10 oktober 2023 · Shuttle Pharma to Participate in the Lytham Partners Fall 2023 Investor Conference · Persbericht

25 september 2023 · Shuttle Pharma Announces Results of Pre-IND Meeting with FDA for Ropidoxuridine Phase II Clinical Trial for Patients with Glioblastoma · Persbericht

13 september 2023 · Shuttle Pharma Participates in Hampton University Proton Therapy Institute Prostate Cancer & Men's Health Fair · Persbericht

11 september 2023 · Shuttle Pharma Expands Patent Coverage on HDAC Inhibitor Platform · Persbericht

29 augustus 2023 · Shuttle Pharma's Selective HDAC6 Inhibitor Shown to Stimulate Innate Immune Response in Pre-clinical Studies, as Reported in Molecular Cancer Therapeutics · Persbericht

15 augustus 2023 · Shuttle Pharmaceuticals Provides Second Quarter 2023 Corporate Update · Persbericht

3 augustus 2023 · Shuttle Pharmaceuticals Completes Manufacturing of Active Pharmaceutical Ingredient (API) for Use in Clinical Trial · Persbericht

26 mei 2023 · Shuttle Pharmaceuticals Provides First Quarter 2023 Corporate Update · Persbericht

17 mei 2023 · Shuttle Pharmaceuticals to Participate in the Lytham Partners Spring 2023 Investor Conference · Persbericht

22 maart 2023 · Shuttle Pharmaceuticals Enters Research Agreement with Georgetown University for Testing of Small Molecule Radiation Sensitizers and Immune Activation Candidates · Persbericht

Mijn selecties